Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis
Tuberculosis (TB) treatment is hampered by monotherapy limitations and phenotypic drug tolerance, citing the need for effective drug combinations. The mycobacterial ele...
<a href="https://www.fiercebiotech.com/biotech/contineums-jj-partnered-ms-drug-fails-improve-vision-phase-2" hreflang="en">Contineum's J&J-partnered MS drug fails to improve vision in phase 2</a>
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.
<a href="https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2" hreflang="en">J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2</a>
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibo...
Regulatory actions for Nov. 25, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Celltrion, Hen...
UK-US drug pricing deal could come as early as this week, sources say
A major drug price deal between the US and UK government could be finalized as early as this week, two UK-based sources familiar with the matter told Endpoints News on...
Bayer’s asundexian hits phase III stroke goal in win for FXIa drugs
Detailed data will be forthcoming at a scientific congress, but Bayer AG’s positive top-line readout from its phase III study testing oral factor XIa (FXIa) inhibitor a...
Regulatory actions for Nov. 24, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Sangamo.
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
Teva loses IRA drug pricing challenge in DC federal court
Teva’s challenge against Medicare negotiations fell flat in DC federal court, marking another loss for the pharma industry. US District Judge Sparkle Sooknanan said Thu...
Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial
Contineum Therapeutics reported a Phase 2 failure in multiple sclerosis on Thursday afternoon, but most analysts don’t seem to view the miss as catastrophic. Contineum...
GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing deal
GSK subsidiary Tesaro and AnaptysBio are at legal loggerheads over a licensing pact concerning the cancer drug Jemperli that dates back to 2014. On Thursday, GSK said T...
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...